361 related articles for article (PubMed ID: 17852912)
21. Antimicrobial resistance in Burkholderia pseudomallei.
Vorachit M; Chongtrakool P; Arkomsean S; Boonsong S
Acta Trop; 2000 Feb; 74(2-3):139-44. PubMed ID: 10674642
[TBL] [Abstract][Full Text] [Related]
22. The antibiotics of choice for the treatment of melioidosis in Indian set up.
Shaw T; Tellapragada C; Eshwara VK; Bhat HV; Mukhopadhyay C
Indian J Med Microbiol; 2016; 34(3):353-4. PubMed ID: 27514960
[TBL] [Abstract][Full Text] [Related]
23. Reduced susceptibility of Malaysian clinical isolates of Burkholderia pseudomallei to ciprofloxacin.
Liew FY; Tay ST; Puthucheary SD
Trop Biomed; 2011 Dec; 28(3):646-50. PubMed ID: 22433895
[TBL] [Abstract][Full Text] [Related]
24. In-vitro activity of β-lactams/trimethoprim-sulfamethoxazole combinations against different strains of Burkholderia pseudomallei.
Mohamad NI; Harun A; Hasan H; Deris ZZ
Trop Biomed; 2022 Mar; 39(1):11-16. PubMed ID: 35225295
[TBL] [Abstract][Full Text] [Related]
25. In-vitro susceptibility of Burkholderia pseudomallei to cefoperazone-sulbactam combination.
Koay AS; Rohani MY; Cheong YM
Med J Malaysia; 1997 Jun; 52(2):158-60. PubMed ID: 10968074
[TBL] [Abstract][Full Text] [Related]
26. In vitro interactions between cotrimoxazole and doxycycline in Burkholderia pseudomallei: how important is this combination in maintenance therapy of melioidosis?
Saraya S; Soontornpas C; Chindavijak B; Mootsikapun P
Indian J Med Microbiol; 2009; 27(1):88-9. PubMed ID: 19172079
[No Abstract] [Full Text] [Related]
27. Burkholderia pseudomallei animal and human isolates from Malaysia exhibit different phenotypic characteristics.
Lee SH; Chong CE; Lim BS; Chai SJ; Sam KK; Mohamed R; Nathan S
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):263-70. PubMed ID: 17350202
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of biapenem against Burkholderia pseudomallei.
Thamlikitkul V; Trakulsomboon S
Int J Antimicrob Agents; 2010 May; 35(5):514. PubMed ID: 20188524
[No Abstract] [Full Text] [Related]
29. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems.
Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J
J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233
[TBL] [Abstract][Full Text] [Related]
30. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei from Thailand.
Saiprom N; Amornchai P; Wuthiekanun V; Day NP; Limmathurotsakul D; Peacock SJ; Chantratita N
Int J Antimicrob Agents; 2015 May; 45(5):557-9. PubMed ID: 25758020
[No Abstract] [Full Text] [Related]
31. Five-year surveillance for Burkholderia pseudomallei in Thailand from 2000 to 2004: prevalence and antimicrobial susceptibility.
Paveenkittiporn W; Apisarnthanarak A; Dejsirilert S; Trakulsomboon S; Thongmali O; Sawanpanyalert P; Aswapokee N
J Med Assoc Thai; 2009 Aug; 92 Suppl 4():S46-52. PubMed ID: 21298845
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.
Bugrysheva JV; Sue D; Gee JE; Elrod MG; Hoffmaster AR; Randall LB; Chirakul S; Tuanyok A; Schweizer HP; Weigel LM
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396541
[No Abstract] [Full Text] [Related]
33. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods.
Almuzara M; Limansky A; Ballerini V; Galanternik L; Famiglietti A; Vay C
Int J Antimicrob Agents; 2010 Jan; 35(1):68-71. PubMed ID: 19889520
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial Susceptibility of Western Hemisphere Isolates of
Bugrysheva JV; Lascols C; McLaughlin HP; Gee JE; Elrod MG; Sue D
Microb Drug Resist; 2021 Sep; 27(9):1176-1185. PubMed ID: 33570476
[TBL] [Abstract][Full Text] [Related]
35. Diffusion and activity of antibiotics against Burkholderia pseudomallei biofilms.
Pibalpakdee P; Wongratanacheewin S; Taweechaisupapong S; Niumsup PR
Int J Antimicrob Agents; 2012 Apr; 39(4):356-9. PubMed ID: 22364716
[TBL] [Abstract][Full Text] [Related]
36. Melioidosis: an emerging infection in Taiwan?
Hsueh PR; Teng LJ; Lee LN; Yu CJ; Yang PC; Ho SW; Luh KT
Emerg Infect Dis; 2001; 7(3):428-33. PubMed ID: 11384520
[TBL] [Abstract][Full Text] [Related]
37. Melioidosis presenting as sepsis syndrome: a case report.
Redondo MC; Gómez M; Landaeta ME; Ríos H; Khalil R; Guevara RN; Palavecino S; Figuera M; Caldera J; Rivera R; Calvo A; Vitelli J; Morón M; Nuñez MJ
Int J Infect Dis; 2011 Mar; 15(3):e217-8. PubMed ID: 21195650
[TBL] [Abstract][Full Text] [Related]
38. Identification and Characterization of Burkholderia pseudomallei from Localized Pyogenic Infections in Eastern India: A Clinico-Microbiological Study.
Purushotham P; Mohanty S; Chappity P; Mishra TS; Mahapatra A
Am J Trop Med Hyg; 2021 Feb; 104(4):1252-1259. PubMed ID: 33534740
[TBL] [Abstract][Full Text] [Related]
39. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
40. Correlation Between Etest and Reference Broth Microdilution for Antimicrobial Susceptibility Testing of
Lonsway DR; Elrod MG; Kendrick N; Tiller R; Sullivan MM; Edwards JR; Blaney DD; Karlsson M
Microb Drug Resist; 2020 Apr; 26(4):311-318. PubMed ID: 31596673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
